NCT02868632: Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer |
|
|
| Withdrawn | 1 | 0 | US | MEDI4736, Durvalumab, Tremelimumab, CP-675,206, Stereotactic Body Radiation Therapy (SBRT) | NYU Langone Health, AstraZeneca | Pancreatic Cancer | 03/19 | 03/19 | | |